A comprehensive literature and patent review of BPC 157's pharmacology and potential medical applications. Covers BPC 157's pleiotropic effects in tissue injury, IBD, and CNS disorders; its favorable safety profile; its temporary WADA ban in 2022; and the absence of FDA approval due to insufficient clinical trials. Serves as an up-to-date reference for BPC 157's scientific and regulatory status.
Józwiak, Michalina; Bauer, Marta; Kamysz, Wojciech; Kleczkowska, Patrycja